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The search for molecules that can act as potential biomarkers is increasing in the scientific community, including in
the field of psychiatry. The field of proteomics is evolving and its indispensability for identifying biomarkers is clear.
Among proteomic tools, mass spectrometry is the core technique for qualitative and quantitative identification of
protein markers. While significant progress has been made in the understanding of biomarkers for
neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis and Parkinson’s disease, psychiatric
disorders have not been as extensively investigated. Recent and successful applications of mass spectrometry-based
proteomics in fields such as cardiovascular disease, cancer, infectious diseases and neurodegenerative disorders
suggest a similar path for psychiatric disorders. In this brief review, we describe mass spectrometry and its use in
psychiatric biomarker research and highlight some of the possible challenges of undertaking this type of work.
Further, specific examples of candidate biomarkers are highlighted. A short comparison of proteomic with genomic
methods for biomarker discovery research is presented. In summary, mass spectrometry-based techniques may
greatly facilitate ongoing efforts to understand molecular mechanisms of psychiatric disorders.
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Recently, there have been increased efforts to address
psychiatric disorders at the molecular level to under-
stand the pathophysiology and molecular mechanisms
involved. A major step has been the effort to discover
putative biomarkers specific to psychiatric disorders
[1,2]. Biological markers (biomarkers) are measurable
physiological indicators of disease or a disorder and bear
a tremendous potential for diagnosis and treatment
monitoring. Biomarker research employs mainly “omic”
technologies (genomics, transcriptomics and proteo-
mics) as shown for example, in the transcriptomics
profiling of psychosis or mood disorders as well as the
proteomic profiling of bipolar disorder [3-5]. Though
genomics and transcriptomics were among the first tools
used, they are being increasingly substituted by* Correspondence: awoods@clarkson.edu
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distribution, and reproduction in any mediumproteomics. However, all approaches have individual as
well as common advantages and challenges. One collective
challenge of both proteomics and genomics lies in the
confirmation or validation of identified proteins [6]. Re-
gardless of the approach, the ultimate goal is the discovery
of a list of valid, reliable and selective biomarkers.
In this review, we highlight the contribution of proteo-
mics, especially of mass spectrometry (MS) to biomarker
discovery research for psychiatric disorders. Proteomics
have been of considerable benefit to other disciplines,
which suggests that this approach may also be of great
interest to psychiatry. For example proteomic analysis is
used clinically to identify bacterial subtypes in cystic
fibrosis [7], cystitis [8] and septic shock [9], directing
treatment. Other clinical uses of proteomics/MS include
measurement of renal function [10] and newborn
screening for a variety of disorders [11,12]. Proteomic
biomarker discovery holds great promise in cancer re-
search for clinical diagnostics, based on the identifica-
tion of new cancer biomarkers that might open new
roads to improved diagnosis and treatment [13-15].
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suggesting diagnostic potential [16]. These are but a few
examples illustrating the clinical use and potential of
MS-based proteomics.
Our intention is to speak to all involved partners in
psychiatric research: psychiatrists, neuroscientists, prote-
omic researchers in order to bring them together to find
answers to some of the questions raised here. Therefore,
we first describe the basics of psychiatric disorders and
of mass spectrometry, before looking at the connection
between both disciplines.
Example biomarkers in psychiatric disorders
Biomarkers are not routinely used for clinical detection
of psychiatric disorders while other widespread medical
conditions such as diabetes and heart disease are identi-
fied and monitored using several markers [17-19]. There
have been numerous studies pointing towards genetic
and epigenetic etiologies for psychiatric disorders. By na-
ture, psychiatric disorders may have a concerted pathway
that orchestrates the down-regulation of multiple genes
through epigenetic mechanisms. For instance, DNA
methylations or histone modifications in combination
with GABAergic and glutamatergic gene promoters are
proposed to be critical elements in the pathogenesis of
schizophrenia and bipolar disorder as demonstrated by
decreased protein levels of GABA-ergic neuronal
markers (reelin, RELN and glutamic acid decarboxylase
67, GAD67) [20-23]. Additionally, it has been suggested
that polymorphisms in ADRA2A (alpha-2A adrenergic
receptor), DRD3 (dopamine receptor D3), DBH (dopamine
β-hydroxylase) and SNAP-25 (25 kDa synaptosomal-
associated protein) are individually or collectively risk
factors for schizophrenia [24-27]. As just discussed,
there are many potential genetic sources from which
biological markers could be retrieved in psychiatric
disorders. However, non-genomic biomarkers, such as
protein/peptide biomarkers, also hold promise.
Due to their broad variety, psychiatric disorders have
been hypothesized to be associated with the dysfunction
of many biological pathways and networks. For example,
impairment of the corticotropin releasing factor (CRF)
system is proposed to contribute to symptoms in psychi-
atric disorders such as depression, obsessive compulsive
disorder, post-traumatic stress disorder and substance
use disorders [28-32]. Depression has been associated
with low plasma levels of antioxidants such as vitamin
E, zinc, glutathione (GSH), coenzyme Q10, selenium
[33-38].
Dopamine (DA) and noradrenaline (NE) have been
proposed to play a major role in modulating high-level
executive functions that are impaired in attention-deficit/
hyperactivity disorder (ADHD), for example planning and
attention, functions related to fronto-striato-cerebellarcircuits (ADHD) [39]. Dopaminergic disturbances have
also been posited to underlie the hyperactivity observed in
ADHD, likely along with other neurotransmitter systems
[40]. Reflecting a possible disturbance in the dopaminergic
system, dopamine transporter (DAT) levels are increased
in individuals with ADHD [39,41]. A recent meta-analysis
confirms that peripheral markers related to the dopamin-
ergic and noradrenergic systems (as well as additional
markers such as zinc and cortisol), may be of future use
for ADHD diagnosis and treatment [42].
A current common approach in mass spectrometric
characterization of proteins is differential gel-based
quantitative proteomics [43,44]. It consists of separating
samples, (from subjects with disorders and unaffected
controls), by gel electrophoresis (usually 2D-gel electro-
phoresis). Gel bands are then analysed by tryptic diges-
tion and LC-MS/MS for protein identification and
quantification. Results are often validated by western
blot or ELISA. Using this approach (2D-PAGE and LCQ
DECA XP PLUS ion trap mass spectrometer), Ditzen
and colleagues identified glyoxalase I (GLX1) and eno-
lase phosphatase (EP) as protein markers that could be
risk markers for anxiety in a mouse model of trait anx-
iety [45]. A separate study utilized this technique to
identify 59 potential biomarkers in cerebral cortex and
11 in amygdala in post-mortem brain tissue from suicide
victims [46]. Several of these proteins were already pro-
posed as psychiatric protein biomarkers. In another
study, focusing on major depressive disorder (MDD) in a
rat model, 27 potential protein markers with roles in
neurogenesis, oxidative metabolism, transcription and
signal transduction, were identified by 2D-gel and
MALDI-TOF-MS [47]. Shotgun proteomics (explained
later) was also employed for the study of brain tissue of
samples from MDD patients using SDS-PAGE and
nanoHPLC-MSE (Q-TOF MS) and produced a possible
means for categorizing different subtypes of MDD
patients based on proteomic profile patterns [48].
These protein fingerprints resulted from significantly,
differentially-expressed proteins between subgroups of
MDD patients (with and without psychosis) as well as be-
tween MDD subjects and healthy controls. Differentially-
expressed proteins between MDD patients and healthy
controls were those involved in metabolism, transport,
cell communication and signaling, cell growth and
maintenance, protein metabolism and regulation of
nucleic acid metabolism. The use of biomarkers to
diagnose depression is of great interest and promise,
particularly to direct the selection of therapies. How-
ever, further studies are needed before proteomics can
be used clinically for depression [49].
The discovery of potential biomarkers for depression
could be expanded to other related psychiatric disorders
since depression is comorbid with many psychiatric,
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A proteomic study reported the association of protein
markers of MDD with neurodegenerative diseases such
as Huntington and Alzheimer as well as schizophrenia
confirming some sense of commonality among neuro-
logical and psychiatric disorders at the molecular level
[27]. Interestingly, this connection is already observed at
the symptomatic level as neuropsychiatric disorders
overlap in their symptoms. In this regard, there is a need
for identification of a signature of a set of biomarkers
rather than relying on a few markers [6,50].
Mass spectrometry
Proteomics is a fast-rising and promising field with new
developments and improvements still taking place. As
mentioned, one core method in proteomics is MS. For
MS analysis of proteins, proteins are initially separated
(biochemically fractionated) via a variety of methods, for
example, electrophoresis or chromatography [2]. Once
fractionation has been performed, proteins are analysed
by MS. A mass spectrometer is made of three main
parts: ionization source, mass analyser and detector. The
protein sample is ionized using an ionization source.
The sample then travels through a mass analyser
according to the mass over charge (m/z). The ionized
sample then hits the detector, where spectra are
recorded. Spectra serve as protein “fingerprints” that can
be used to identify proteins, for example. For a more
detailed description of MS tailored to those working in
psychiatric research, the reader may refer to Woods
et al., 2012 [2].
Due to high-performing MS instruments, simplified
analytical workflows and versatile data analysis, mass
spectrometry is applicable to almost every area of the life
sciences and potentially even far beyond [51-54]. The
two most common ionization methods are electrospray
ionization (ESI) and matrix-assisted laser desorption/
ionization (MALDI). Currently a multitude of analyzers
exist for different types of applications, including, quad-
rupole (Q), time-of-flight (TOF) and ion trap (IT). Trad-
itionally, MALDI sources are coupled with TOF or
TOF/TOF mass analyzers due to their pulse mode of
action.
In shotgun proteomics, liquid chromatography (LC) is
coupled to mass spectrometry for identification of pro-
teins. In this case, ESI is the ionization mode preferred
for the characterization of biomolecules, ionic and very
labile organic and organometallic compounds though
LC-MALDI-MS is also an eventuality [55,56]. Bottom-
up proteomics represents the case where samples are
first digested to generate peptides which can then be an-
alyzed by mass spectrometry while top-down proteomics
designate a method where the mass of the entire protein
is being measured by a mass spectrometer followed byits sequencing. The main advantage of LC-MALDI-MS
over LC-ESI-MS is the robustness of LC-MALDI-MS
in resisting to very harsh LC conditions (lower sup-
pression effects) and the high mass-to-charge (m/z)
range of the TOF mass analyzer. The disadvantage of
LC-MALDI-MS is the difficulty of spotting directly
from the LC apparatus. However, LC-MALDI is only
rarely used.
With MS, proteins can be identified by measuring the
m/z of gas phase ions. We distinguish between gel-
based, one-dimensional and two-dimensional gel electro-
phoresis mass spectrometry (1-DE, 2-DE and MS)
[57-64] and non-gel based liquid chromatography/mass
spectrometry (LC/MS). In 2-DE, proteins are separated
in a first dimension according to their charge or isoelec-
tric point (pI) and in a second dimension depending on
their molecular weight [65,66]. For visualization of pro-
tein bands, the gel can be stained either with the dye
coomassie blue or silver stained or by fluorescently la-
beling the samples before 2-DE. For mass spectrometry
analysis, gel bands are removed, and undergo several
other steps to generate peptides in bottom-up and
shotgun proteomics [51,53,67,68]. Compared to LC/MS,
2-DE methods are more reproducible and robust. How-
ever, 2-DE methods are very labor-intensive and not
very suitable for hydrophobic, very large or small, basic
proteins and complex sample mixtures. However, the
weaknesses of 2-DE methods represent the strengths of
LC/MS-based methods. LC-MS methods are appreciated
for their ability in the analysis of very complex protein
samples and extreme proteins (e.g. membrane proteins)
and therefore offer better proteome coverage in com-
parison to 2-DE-based techniques.
For quantification, a label-free or label-based [69] ap-
proach can be selected. In general, quantitation is car-
ried out with internal standards which are added to the
sample prior to any sample preparation step in order to
exclude any variations resulting from the sample prepar-
ation. Non-gel, label-based approaches consist in label-
ing peptides prior to LC separation using mostly the
three following techniques: 1) isobaric tags for relative
and absolute quantitation, iTRAQ (iTRAQ® Applied
Biosystems, AB Sciex, Foster City, CA, USA) [70,71]; 2)
isotope-coded affinity tags, ICAT [72] and 3) stable iso-
tope labeling of amino acids in cell culture, SILAC
[53,73,74]. These internal isotopically labeled analogs
have the same physico-chemical properties, meaning
same retention time, fragmentation pattern and extrac-
tion efficiency as their endogenous sample-intrinsic
counterparts but differ in their mass shift as a result of
the incorporation of heavy or light isotopes in their
structure. However, isotopically labeled analogs present
some limitations due to their targeted chemistry (e.g.
cysteines for ICAT, intensive sample separation and
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tral counting), quantitation is based on the number of
spectra generated for a reference protein or peptide.
Though mostly reported for neurodegenerative prote-
omic studies [71,75,76], these quantitative techniques
can also be extended to psychiatric disorders. Another
MS-based quantitation approach that is commonly
applied is the multiple-reaction monitoring (MRM)
technique that is possible on triple quadrupole, linear
ion trap MS instruments. MRM is a robust multiplexed
assay for the accurate and sensitive determination of
protein expression levels and post-translational protein
modifications [77]. Instrument-wise, MALDI is typically
coupled to QqQ mass analyzers resulting in fast and sensi-
tive quantitation [78] that is thought to be able to chal-
lenge established LC-ESI-MS methods in term of linearity,
limit of quantitation, precision and accuracy [79].
Due to the considerable amount of data generated
during a proteomics experiment and the need to extract
as much information as possible from these data, the
field of bioinformatics has become an important tool in
the discovery of biomarkers by proteomics methods and
has been further improved recently [80,81]. The same
can be said of online protein databases (Expasy or
HPRD), search engines (X! Tandem, MASCOT, Sequest),
data management repositories (PRIDE, GPMdb), data
exploration and mining tools (Ingenuity pathways
analysis IPA, GOMiner, ProteinLounge, Scaffold,
ProteinLynx Global Server). To date, proteomics has
been more frequently employed in neurodegenerative
disorders than psychiatric [82] and can and should be
expanded to psychiatric disorders [4].
Comparison of MS-methods with classical biomarker
discovery techniques
With the completion of the Human Genome Project
and the extensive progress made in the field of genomics
together with the possible genetic etiology of some
psychiatric disorders, genetics and molecular biology
represent one of the predominant methods of psychiatric
biomarker discovery. Using chromosome microarray
with probes for both copy number variants and single
nucleotide polymorphisms (SNPs), determination of
disorder-underlying genes and segmental deletions or
duplications is possible. Newly developed methods such
as exome sequencing enable detection of SNPs, gene
regulatory sequences and mutations of protein coding
genes that could be the root of a psychiatric disorder.
However, genomics have some limitations. For example,
genomic methods cannot distinguish splice variants or
proteins with post-translational modifications.
Though genomics was originally the state of the art
discipline for psychiatric biomarker discovery; one can
notice the shift that has been taking place in the lastdecade from genomics- to proteomics-based techniques
[26,83-91]. This shift may be due in part to the fact that
changes at the mRNA level are not necessarily reflected
at the protein level [92,93]. Changes at the protein level
may reflect disorder processes that cannot be detected at
the genomic level. Genomic and proteomic information
may be complementary, contributing to more of a sys-
tems approach to understanding the biology of psychi-
atric disorders [1].
One advantage of genetics in biomarker discovery is
their superior high-throughput. The amount of mRNA
or SNPs that can be analyzed at once is in the tens of
thousands for genetic studies compared to few thousand
for proteomics. Also, due to the non-translation of some
transcripts and the non-secretion of some proteins, tran-
script rather than protein levels are chosen to be moni-
tored. Finally, the isolation of RNA from blood does not
require refrigeration in contrast with plasma and serum
samples and is RNA less susceptible to degradation [94].
In some cases, it would be interesting to pursue both
genomics and proteomics works to seek confirmation or
complementarity of results. Genomic markers and pro-
tein markers may ultimately play interesting and possibly
complementary roles in psychiatric diagnosis, since gen-
omic information may indicate disorder susceptibility.
Due to the ever-changing nature of proteins, proteomic
information is more likely to allow for monitoring of
certain aspects of a disorder, such as severity and re-
sponse to treatment. Multiple markers obtained using
different data-collection approaches (such as genomic,
proteomic, neuroanatomical, brain activity patterns, etc.)
comprising a biomarker signature, could aid differential
diagnosis, particularly since individual markers are likely
to overlap amongst psychiatric syndromes. Indeed, a sys-
tems approach to neuropsychiatric disorders has been
recently proposed, which would address the multifactor-
ial aspects and complexity of psychiatric problems [1],
which would include a consideration of environment,
experience and behavior as well as the data measure-
ments listed above. Mass spectrometry and proteomics
have the potential to be major components of such an
approach.Discussion
There are many challenges and stumbling blocks that
need to be addressed for mass spectrometry to develop
its full potential in psychiatric biomarker research. It is
now well known that more than 20,000 genes are
expressed in the brain and more than 300 potential
post-translational modifications have been determined
[95]. Further, there is a wide dynamic range in regard to
the relative abundance of proteins in brain cells and tis-
sues or in response to external factors.
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the distinct description of most psychiatric disorders is
still not well defined. Therefore, there is a dire need for
discovery of new proteins [54,96-99] and of molecular
biomarkers to categorize, prognosticate, monitor or treat
psychiatric disorders [44]. Another challenge is the exist-
ence of adequate model systems that mimic exactly the
pathophysiological situations taking place in the brain. It
is difficult to assess cognitive and neuropsychiatric
symptoms such as hallucinations or suicidal ideations in
any model organisms. As for human studies, the prob-
lem resides in the availability of well-characterized hu-
man material taken according to international standard
protocols. Further, large pools of samples are required
for high-throughput analyses and data, and also due to
individual variability. Regarding databases, software or
programs used in genomics and proteomics there is a
risk that genes and proteins that are well-characterized
and described will have a higher detection rate than
those with unknown function.
Mass spectrometry can and will most likely play a
major role in the identification of psychiatric bio-
markers. Several recent developments and innovations
have occurred in the field of mass spectrometry in par-
ticular and proteomics in general. These include in-
creased machine sensitivity allowing detection of
proteins found at low concentrations and improved soft-
ware allowing not only protein detection, but even the
analysis of an entire protein pathway. These advance-
ments make this discipline of increasing potential utility
to further the understanding of molecular mechanisms
underlying the pathophysiology of psychiatric disorders.
Several possible advantages of mass spectrometry exist
with regard to possible diagnostic use. For one, mass
spectrometry can identify all proteins in a sample,
whereas other techniques require that the protein of
interest is targeted. Second, analysis of biomaterials such
as blood, saliva or urine is convenient and non-invasive
(in the case of saliva and urine). Third, the sensitivity of
recently developed machinery is extremely high, increas-
ing the potential that peripheral bodily fluids may actu-
ally reflect central nervous system protein contents.
Finally, protein marker changes could potentially pre-
cede behavioral changes, giving an earlier indication of
whether a treatment is working. This may be particularly
useful in psychiatry, since treatment effects are often not
immediately measurable in people with psychiatric prob-
lems. The determination of proteome fingerprints or
profiles specific to a disorder could open the door to a
new way of discovering biomarkers for the diagnosis,
prognosis, monitoring and treatment of psychiatric
disorders.
Scientists have in some instances thought of bio-
markers as a single biomolecule which is differentiallyexpressed in a unique disease. However, as already men-
tioned above, some psychiatric disorders share similar
symptoms and molecular pathways. It may therefore be
more appropriate to concentrate on a biomarker signa-
ture of multiple molecules which can be altered in order
to monitor and identify a psychiatric disorder [100]. Be-
sides examining peripheral and bodily fluids such as the
cerebrospinal fluid (CSF) or serum, one could consider,
(if available), the use of the primary brain tissue for pro-
teomics experiment. However, to study brain tissue re-
quires a biopsy (available mostly for cancerous tissues or
epilepsy) or post-mortem tissue (quality can be some-
times questionable). Further, psychiatry-based proteo-
mics could also investigate protein-protein interactions
and protein post-translational modifications (PTMs) as
well as the whole proteome. As for the design of the
studies, care should be taken to consider high variability
in age, gender, demographics, race, postmortem interval,
drug treatment, comorbidities and other influencing fac-
tors [101]. Another critical point is the evaluation, inter-
pretation and follow-up of results of proteomics studies.
Traditionally, validation has been performed with bio-
chemical methods such as western blotting and ELISA.
However, these methods are limited by their low high-
throughput capability (mostly western blotting) as well
as the high cost and difficulty associated with the pro-
duction of very specific antibodies (ELISA). Fortunately,
mass spectrometric methods such as MRM are strong
alternatives for the validation of proteins identified in
high-throughput proteomics experiments.
Conclusions
The application of mass spectrometry-based methods
opens a new avenue for the investigation of psychi-
atric disorders with the clear objective of understand-
ing and identifying altered protein pathways as well as
uncovering psychiatric biomarkers for diagnosis, prog-
nosis and treatment monitoring. Eventually mass-
spectrometry may facilitate treatment of psychiatric
disorders through the identification of therapeutic
targets.
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